Grufity logoGrufity logo

TECH

84.69USD-1.72(-1.99%)Market Closed

Bio-Techne Corp

Market Summary

USD84.69-1.72Market Closed
-1.99%

TECH Stock Price

RSI Chart

Valuation

Market Cap

11.6B

Price/Earnings

42.59

Price/Sales

10.48

Price/Cashflow

35.62

MarketCap/EBT

38.45

Price/Sales

Profitability

EBT Margin

27.26%

Return on Equity

15.99%

Return on Assets

11.86%

Fundamentals

Revenue

Revenue (TTM)

1.1B

Revenue Y/Y

4.63%

Revenue Q/Q

-6.44%

Earnings

Earnings (TTM)

292.0M

Earnings Y/Y

28.64%

Earnings Q/Q

45.56%

Price Action

52 Week Range

130.15
(Low)(High)

Last 7 days

-0.1%

Last 30 days

13.9%

Last 90 days

2.9%

Trailing 12 Months

-27.2%

Financial Health

Current Ratio

3.44

Debt/Equity

0.14

Debt/Cashflow

1.34

Investor Care

Dividend Yield

0.36%

Buy Backs (1Y)

0.13%

Diluted EPS (TTM)

7.14

Peers (Alternatives to Bio-Techne)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
41.1B
6.7B
15.08% 3.58%
30.93
6.17
8.42% 34.14%
36.7B
4.7B
3.69% -38.80%
-1.9K
7.81
9.79% -558.28%
28.5B
3.9B
19.96% -3.97%
34.68
7.36
7.75% 11.02%
11.6B
1.1B
13.92% -27.18%
42.59
10.48
13.51% 65.31%
10.1B
801.3M
8.47% -30.79%
63.34
12.97
35.20% 39.92%
MID-CAP
SMALL-CAP
2.0B
137.0M
31.93% -50.56%
-9.53
14.05
12.61% -709.53%
1.1B
159.7M
14.14% -65.84%
-4.68
6.81
19.67% -35.56%
661.5M
23.3M
-6.28% -43.67%
-6.25
28.36
76.56% -106.44%
488.2M
135.3M
-22.87% -81.30%
-3.51
3.42
-2.59% -32.75%
413.2M
110.0M
30.54% -66.08%
-5.25
3.72
3.37% -106.72%
372.0M
132.7M
-1.39% -83.46%
-19.64
2.76
31.03% -107.73%
109.5M
118.0M
6.72% -56.67%
-29.97
0.91
0.97% -269.58%
105.9M
68.8M
4.79% -62.04%
-3.75
1.53
5.65% 26.86%
95.7M
51.6M
-0.71% -16.37%
238.75
1.86
20.72% 150.31%

Financials for Bio-Techne

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue1.1%1,1181,1061,0761,030985
Gross Profit1.1%765756732699666
Operating Expenses3.4%475460447436415
  S&GA Expenses3.5%386373363356339
Earnings Before Taxes12.1%338301229206176
Net Income7.3%292272225211177
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets2.4%2,3512,2952,3002,3052,270
  Current Assets-8.8%552606593590544
    Cash Equivalents-4.2%165173161212196
  Inventory6.3%150141128122117
  Net PPE0.4%224223218212207
  Goodwill5.3%865822828832840
  Current Liabilities-21.8%138176167155134
  Long Term Debt8.7%265243247270288
    LT Debt, Current0%13131313-
Shareholder's Equity2.9%1,7511,7021,7141,7031,639
  Retained Earnings3.5%1,1631,1231,1331,1461,119
  Additional Paid-In Capital2.7%654636616584-
Accumulated Depreciation2.1%216211207201196
Shares Outstanding0.2%3939393939
Minority Interest28.0%-0.76-1.05-0.468-
Float-20,300----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations2.4%333325345346335
  Share Based Compensation6.5%4542444648
Cashflow From Investing-13.0%-109.42-96.85-305.18-269.06-242.50
Cashflow From Financing3.2%-234.97-242.85-59.44-30.60-67.30
  Dividend Payments0.2%50505050
  Buy Backs15.3%18616112286

Risks

What is the probability of a big loss on TECH?

54.6%


Probability that Bio-Techne stock will be more than 20% underwater in next one year

33.1%


Probability that Bio-Techne stock will be more than 30% underwater in next one year.

4.6%


Probability that Bio-Techne stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TECH drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Bio-Techne was unfortunately bought at previous high price.

Returns

Cumulative Returns on TECH

18.3%


10-Year Cumulative Returns

21.3%


7-Year Cumulative Returns

21.2%


5-Year Cumulative Returns

16.8%


3-Year Cumulative Returns

What are the long-term rolling returns for TECH?

FIve years rolling returns for Bio-Techne.

Which funds bought or sold TECH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Toroso Investments, LLC
ADDED
4.8
-59,000
360,000
0.01%
2022-11-22
CVA Family Office, LLC
-
-
-
3,000
-%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
4,635,000
4,635,000
0.05%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-4,303,000
18,093,000
0.03%
2022-11-18
National Pension Service
ADDED
1.58
-3,641,000
18,699,000
0.04%
2022-11-18
Power Corp of Canada
-
-
160,000
1,445,000
0.22%
2022-11-17
CENTRAL TRUST Co
UNCHANGED
-
-18,000
82,000
-%
2022-11-17
Grandeur Peak Global Advisors, LLC
NEW
-
2,766,000
2,766,000
0.17%
2022-11-17
M&T Bank Corp
-
-
-76,000
463,000
-%
2022-11-16
ASHFORD CAPITAL MANAGEMENT INC
REDUCED
-30.88
-559,000
730,000
0.11%

1–10 of 47

Latest Funds Activity

Are funds buying TECH calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own TECH

Bio-Techne News

Seeking Alpha

BBH: Portfolio Of Large-Cap Biotechnology Stocks Has Delivered Strong Returns.27 hours ago

TECH Fair Value

Recent SEC filings of Bio-Techne

View All Filings
Date Filed Form Type Document
Nov 07, 2022
10-Q
Quarterly Report
Nov 01, 2022
8-K
Current Report
Oct 31, 2022
4
Insider Trading
Oct 31, 2022
4
Insider Trading
Oct 31, 2022
4
Insider Trading
Oct 31, 2022
4
Insider Trading
Oct 31, 2022
4
Insider Trading
Oct 31, 2022
4
Insider Trading
Oct 31, 2022
4
Insider Trading
Oct 31, 2022
4
Insider Trading

Latest Insider Trading transactions for TECH

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-27
STEER RANDOLPH C
ACQUIRED
-
-
338
-
2022-10-27
VESSEY RUPERT
ACQUIRED
-
-
338
-
2022-10-27
BAUMGARTNER ROBERT V
ACQUIRED
-
-
338
-
2022-10-27
KEEGAN JOSEPH D
ACQUIRED
-
-
338
-
2022-10-27
HIGGINS JOHN L
ACQUIRED
-
-
338
-
2022-10-27
Nusse Roeland
ACQUIRED
-
-
338
-
2022-10-27
Seth Alpna
ACQUIRED
-
-
338
-
2022-10-27
Bushman Julie L
ACQUIRED
-
-
338
-
2022-08-23
Kelderman Kim
ACQUIRED
99,967.1
150.78
663
Pres. Diagnostics & Genom
2022-08-11
HIGGINS JOHN L
SOLD
-197,322
385.395
-512
-

1–10 of 50

Charles R. Kummeth
2600
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

TECH Income Statement

2022-09-30
Condensed Consolidated Statements of Earnings and Comprehensive Income - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Condensed Consolidated Statements of Earnings and Comprehensive Income  
Net sales$ 269,655$ 257,719
Cost of sales90,06086,722
Gross margin179,595170,997
Operating expenses:  
Selling, general and administrative99,37586,175
Research and development23,90321,600
Total operating expenses123,278107,775
Operating income56,31763,222
Other income (expense)47,3994,161
Earnings before income taxes103,71667,383
Income taxes (benefit)13,982(1,598)
Net earnings, including noncontrolling interest89,73468,981
Net earnings (loss) attributable to noncontrolling interest179(634)
Net earnings attributable to Bio-Techne89,55569,615
Other comprehensive income (loss):  
Foreign currency translation adjustments(21,457)(8,646)
Foreign currency translation reclassified to earnings with Eminence deconsolidation119 
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 84,6951,682
Other comprehensive income (loss)(16,643)(6,964)
Other comprehensive income (loss) attributable to noncontrolling interest(33)(39)
Other comprehensive income (loss) attributable to Bio-Techne(16,610)(6,925)
Comprehensive income attributable to Bio-Techne$ 72,945$ 62,690
Earnings per share attributable to Bio-Techne:  
Basic$ 2.28$ 1.78
Diluted$ 2.21$ 1.69
Weighted average common shares outstanding:  
Basic39,23239,094
Diluted40,54341,158

TECH Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Jun. 30, 2022
Current assets:  
Cash and cash equivalents$ 165,257$ 172,567
Short-term available-for-sale investments37,81874,462
Accounts receivable, less allowance for doubtful accounts of $2,496 and $2,568, respectively174,174194,548
Inventories150,009141,123
Other current assets24,77322,856
Total current assets552,031605,556
Property and equipment, net224,098223,242
Right of use asset69,74565,556
Goodwill865,418822,101
Intangible assets, net585,534531,522
Other assets53,89546,828
Total assets2,350,7212,294,805
Current liabilities:  
Trade accounts payable30,47533,865
Salaries, wages and related accruals32,55761,953
Accrued expenses13,79017,886
Contract liabilities22,05923,406
Income taxes payable17,27013,237
Operating lease liabilities - current12,11511,928
Contingent consideration payable7,400 
Current portion of long-term debt obligations 12,500
Other current liabilities1,9631,243
Total current liabilities137,629176,018
Deferred income taxes112,92098,994
Long-term debt obligations264,661243,410
Long-term contingent consideration payable8,1005,000
Operating lease liabilities64,75658,133
Other long-term liabilities11,50112,239
Bio-Techne's Shareholders' equity:  
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding00
Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 39,232,094 and 39,160,000, respectively392392
Additional paid-in capital680,057653,657
Retained earnings1,162,5151,122,921
Accumulated other comprehensive loss(91,810)(75,200)
Total Bio-Techne's shareholders' equity1,751,1541,701,770
Noncontrolling interest (759)
Total shareholders' equity1,751,1541,701,011
Total liabilities and shareholders' equity$ 2,350,721$ 2,294,805